Guinea-BissauTuberculosis profile
Population  2015 1.8 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.6 (0.91–2.4) 85 (49–129)
Mortality (HIV+TB only) 0.95 (0.79–1.1) 51 (43–61)
Incidence  (includes HIV+TB) 6.9 (4.5–9.8) 373 (241–533)
Incidence (HIV+TB only) 1.8 (1.1–2.6) 97 (60–142)
Incidence (MDR/RR-TB)** 0.21 (0–0.49) 11 (0–27)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.38 (0.11–0.64) 2.3 (0.92–3.6) 2.7 (1–4.3)
Males 0.46 (0.26–0.66) 3.8 (2.6–5) 4.2 (2.8–5.6)
Total 0.83 (0.51–1.2) 6 (4.5–7.6) 6.9 (4.5–9.8)
TB case notifications, 2015  
Total cases notified 2 141
Total new and relapse 2 133
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 70%
          - % pulmonary 95%
          - % bacteriologically confirmed among pulmonary 74%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 31% (22–48)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.38 (0.22–0.61)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 390 26%
          - on antiretroviral therapy 161 41%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  65
(0–140)
Estimated % of TB cases with MDR/RR-TB 2.8% (0.1–6.7) 21% (2.2–39)  
% notified tested for rifampicin resistance 10% 16% 208
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 17, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 15, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 81% 2 234
Previously treated cases, excluding relapse, registered in 2014 100% 1
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 40% 15
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 3.8
Funding source: 3% domestic, 41% international, 56% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-06 Data: www.who.int/tb/data